Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) have been given an average recommendation of “Moderate Buy” by the eight brokerages that are presently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $43.71.

A number of research analysts have weighed in on ARWR shares. Chardan Capital reiterated a “buy” rating and issued a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, May 13th. HC Wainwright reiterated a “buy” rating and issued a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, May 20th. Wall Street Zen upgraded shares of Arrowhead Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, June 14th. Finally, Citigroup decreased their price objective on shares of Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a “neutral” rating for the company in a research report on Tuesday, May 13th.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In related news, CEO Christopher Richard Anzalone sold 50,800 shares of the company’s stock in a transaction dated Friday, April 11th. The shares were sold at an average price of $11.49, for a total transaction of $583,692.00. Following the completion of the transaction, the chief executive officer owned 3,921,255 shares in the company, valued at $45,055,219.95. This represents a 1.28% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 4.30% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of ARWR. Charles Schwab Investment Management Inc. raised its position in shares of Arrowhead Pharmaceuticals by 1.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,017,720 shares of the biotechnology company’s stock worth $19,133,000 after purchasing an additional 10,785 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in Arrowhead Pharmaceuticals during the 4th quarter valued at about $651,000. Edgestream Partners L.P. purchased a new stake in Arrowhead Pharmaceuticals during the 4th quarter valued at about $2,264,000. King Luther Capital Management Corp purchased a new stake in Arrowhead Pharmaceuticals during the 4th quarter valued at about $1,447,000. Finally, Wealthfront Advisers LLC purchased a new stake in Arrowhead Pharmaceuticals during the 4th quarter valued at about $2,060,000. Institutional investors and hedge funds own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Trading Down 0.7%

NASDAQ ARWR opened at $16.78 on Friday. The company has a market capitalization of $2.32 billion, a PE ratio of -11.99, a P/E/G ratio of 19.75 and a beta of 0.93. The company has a fifty day moving average of $15.45 and a 200 day moving average of $16.43. Arrowhead Pharmaceuticals has a 1 year low of $9.57 and a 1 year high of $30.41. The company has a debt-to-equity ratio of 0.31, a current ratio of 5.15 and a quick ratio of 5.15.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its earnings results on Monday, May 12th. The biotechnology company reported $2.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $2.81. The business had revenue of $542.71 million for the quarter, compared to analyst estimates of $116.27 million. During the same quarter in the prior year, the firm earned ($1.02) earnings per share. Research analysts forecast that Arrowhead Pharmaceuticals will post -2.42 earnings per share for the current year.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.